PDF(Pubmed)
Abstract：
OBJECTIVE: Pregnancy and the postpartum period are increasingly recognised as sensitive windows for cardiometabolic disease risk. Growing evidence suggests environmental exposures, including endocrine-disrupting chemicals (EDCs), are associated with an increased risk of pregnancy complications that are associated with long-term cardiometabolic risk. However, the impact of perinatal EDC exposure on subsequent cardiometabolic risk post-pregnancy is less understood. The Environmental Reproductive and Glucose Outcomes (ERGO) Study was established to investigate the associations of environmental exposures during the perinatal period with post-pregnancy parental cardiometabolic health.
METHODS: Pregnant individuals aged ≥18 years without pre-existing diabetes were recruited at <15 weeks of gestation from Boston, Massachusetts area hospitals. Participants completed ≤4 prenatal study visits (median: 12, 19, 26, 36 weeks of gestation) and 1 postpartum visit (median: 9 weeks), during which we collected biospecimens, health histories, demographic and behavioural data, and vitals and anthropometric measurements. Participants completed a postpartum fasting 2-hour 75 g oral glucose tolerance test. Clinical data were abstracted from electronic medical records. Ongoing (as of 2024) extended post-pregnancy follow-up visits occur annually following similar data collection protocols.
RESULTS: We enrolled 653 unique pregnancies and retained 633 through delivery. Participants had a mean age of 33 years, 10% (n=61) developed gestational diabetes and 8% (n=50) developed pre-eclampsia. Participant pregnancy and postpartum urinary phthalate metabolite concentrations and postpartum glycaemic biomarkers were quantified. To date, studies within ERGO found higher exposure to phthalates and phthalate mixtures, and separately, higher exposure to radioactive ambient particulate matter, were associated with adverse gestational glycaemic outcomes. Additionally, certain personal care products used in pregnancy, notably hair oils, were associated with higher urinary phthalate metabolite concentrations, earlier gestational age at delivery and lower birth weight.
UNASSIGNED: Future work will leverage the longitudinal data collected on pregnancy and cardiometabolic outcomes, environmental exposures, questionnaires, banked biospecimens and paediatric data within the ERGO Study.
METHODS: Pregnant individuals aged ≥18 years without pre-existing diabetes were recruited at <15 weeks of gestation from Boston, Massachusetts area hospitals. Participants completed ≤4 prenatal study visits (median: 12, 19, 26, 36 weeks of gestation) and 1 postpartum visit (median: 9 weeks), during which we collected biospecimens, health histories, demographic and behavioural data, and vitals and anthropometric measurements. Participants completed a postpartum fasting 2-hour 75 g oral glucose tolerance test. Clinical data were abstracted from electronic medical records. Ongoing (as of 2024) extended post-pregnancy follow-up visits occur annually following similar data collection protocols.
RESULTS: We enrolled 653 unique pregnancies and retained 633 through delivery. Participants had a mean age of 33 years, 10% (n=61) developed gestational diabetes and 8% (n=50) developed pre-eclampsia. Participant pregnancy and postpartum urinary phthalate metabolite concentrations and postpartum glycaemic biomarkers were quantified. To date, studies within ERGO found higher exposure to phthalates and phthalate mixtures, and separately, higher exposure to radioactive ambient particulate matter, were associated with adverse gestational glycaemic outcomes. Additionally, certain personal care products used in pregnancy, notably hair oils, were associated with higher urinary phthalate metabolite concentrations, earlier gestational age at delivery and lower birth weight.
UNASSIGNED: Future work will leverage the longitudinal data collected on pregnancy and cardiometabolic outcomes, environmental exposures, questionnaires, banked biospecimens and paediatric data within the ERGO Study.
摘要：
目的：妊娠和产后越来越被认为是心血管代谢疾病风险的敏感窗口。越来越多的证据表明环境暴露，包括内分泌干扰化学物质（EDCs），与妊娠并发症的风险增加相关，而妊娠并发症与长期心脏代谢风险相关。然而,围产期EDC暴露对妊娠后心脏代谢风险的影响尚不清楚.建立了环境生殖和葡萄糖结果（ERGO）研究，以调查围产期环境暴露与妊娠后父母心脏代谢健康的关系。
方法：在妊娠<15周时，从波士顿招募年龄≥18岁且没有预先存在糖尿病的孕妇，马萨诸塞州医院。参与者完成≤4次产前研究访视（中位数：妊娠12、19、26、36周）和1次产后访视（中位数：9周），在此期间，我们收集了生物标本，健康史,人口和行为数据，生命体征和人体测量。参与者完成了产后空腹2小时75g口服葡萄糖耐量试验。从电子病历中提取临床数据。根据类似的数据收集方案，每年进行（截至2024年）延长的妊娠后随访。
结果：我们登记了653例独特妊娠，并保留了633例分娩。参与者的平均年龄为33岁，10％（n=61）患有妊娠糖尿病，8％（n=50）患有先兆子痫。对参与妊娠和产后尿邻苯二甲酸酯代谢物浓度和产后血糖生物标志物进行定量。迄今为止,ERGO内部的研究发现，邻苯二甲酸酯和邻苯二甲酸酯混合物的暴露程度更高，分开,对放射性环境颗粒物的暴露程度更高，与不良妊娠血糖结局相关。此外,怀孕期间使用的某些个人护理产品，特别是头发油，与较高的尿邻苯二甲酸酯代谢物浓度有关，分娩胎龄较早，出生体重较低。
■未来的工作将利用收集的关于妊娠和心脏代谢结果的纵向数据，环境暴露,问卷，ERGO研究中的库存生物标本和儿科数据。
方法：在妊娠<15周时，从波士顿招募年龄≥18岁且没有预先存在糖尿病的孕妇，马萨诸塞州医院。参与者完成≤4次产前研究访视（中位数：妊娠12、19、26、36周）和1次产后访视（中位数：9周），在此期间，我们收集了生物标本，健康史,人口和行为数据，生命体征和人体测量。参与者完成了产后空腹2小时75g口服葡萄糖耐量试验。从电子病历中提取临床数据。根据类似的数据收集方案，每年进行（截至2024年）延长的妊娠后随访。
结果：我们登记了653例独特妊娠，并保留了633例分娩。参与者的平均年龄为33岁，10％（n=61）患有妊娠糖尿病，8％（n=50）患有先兆子痫。对参与妊娠和产后尿邻苯二甲酸酯代谢物浓度和产后血糖生物标志物进行定量。迄今为止,ERGO内部的研究发现，邻苯二甲酸酯和邻苯二甲酸酯混合物的暴露程度更高，分开,对放射性环境颗粒物的暴露程度更高，与不良妊娠血糖结局相关。此外,怀孕期间使用的某些个人护理产品，特别是头发油，与较高的尿邻苯二甲酸酯代谢物浓度有关，分娩胎龄较早，出生体重较低。
■未来的工作将利用收集的关于妊娠和心脏代谢结果的纵向数据，环境暴露,问卷，ERGO研究中的库存生物标本和儿科数据。
